Methods for preparation of antibody-maytansinoid conjugates
This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.
1. A process for preparing a purified conjugate in a solution, wherein the conjugate comprises a maytansinoid molecule linked to an antibody, the process comprising the steps of:
(a) contacting a maytansinoid molecule comprising a thiol group with a bifunctional linker reagent to covalently attach the linker to the maytansinoid molecule, wherein an excess of maytansinoid molecule relative to the bifunctional linker reagent is used, and thereby prepare an unpurified first mixture comprising the maytansinoid molecule having linkers hound thereto,
(b) conjugating an antibody to the maytansinoid molecule having linkers bound thereto by reacting the unpurified first mixture with the antibody in a solution having a pH from about 4 to about 9 to prepare a second mixture, and
(c) subjecting the second mixture to tangential flow filtration, dialysis, gel filtration, adsorptive chromatography, selective precipitation or a combination thereof to thereby prepare the purified conjugate.
2. The process of claim 1 , wherein the second mixture in step (b) is substantially free of undesired cross-linked, hydrolyzed species formed due to intra-molecular or inter-molecular reactions.
3. The process of claim 1 , wherein the maytansinoid molecule is DM1.
4. The process of claim 1 , wherein the maytansinoid molecule is DM4.
5. The process of claim 1 , wherein the antibody is a monoclonal antibody.
6. The process of claim 1 , wherein the antibody is a human or a humanized monoclonal antibody.
7. The process of claim 1 , wherein the antibody is MY9, anti-B4, C242, or an antibody that binds to an antigen selected from the group consisting of EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alpha v beta 3 , alpha v beta 5 , and alpha v beta 6 integrin.
8. The process of claim 6 , wherein the human or the humanized antibody is huMy9-6, huB4, huC242, huN901, DS6, CNTO 95, B-B4, trastuzumab, pertuzumab, bivatuzumab, sibrotuzumab, rituximab, or a human or humanized antibody that binds to an antigen selected from the group consisting of EphA2 receptor CD38, and IGF-IR.
9. The process of claim 1 , wherein the linker is a cleavable or a non cleavable linker.
10. The process of claim 1 , wherein the pH of the solution in step (b) is from about 5 to about 8.7.
11. The process of claim 1 , wherein the pH of the solution in step (b) is from about 6.5 to about 8.5.
12. The process of claim 1 , wherein the process further comprises the step of quenching the excess maytansinoid in the unpurified first mixture with a quenching reagent between steps (a) and (b).
13. The process of claim 12 , wherein the quenching reagent is selected from the group consisting of 4-malcimidobutyric acid, 3-maleimidopropionic acid, N-ethylmaleimide, iodoacetamide, and iodoacetamidopropionic acid.